You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

CEREBYX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Cerebyx patents expire, and when can generic versions of Cerebyx launch?

Cerebyx is a drug marketed by Parke Davis and is included in one NDA.

The generic ingredient in CEREBYX is fosphenytoin sodium. There are eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the fosphenytoin sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Cerebyx

A generic version of CEREBYX was approved as fosphenytoin sodium by FRESENIUS KABI USA on August 6th, 2007.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CEREBYX?
  • What are the global sales for CEREBYX?
  • What is Average Wholesale Price for CEREBYX?
Summary for CEREBYX
Drug patent expirations by year for CEREBYX
Drug Prices for CEREBYX

See drug prices for CEREBYX

Recent Clinical Trials for CEREBYX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
UCB PharmaPhase 4
Emory UniversityPhase 4

See all CEREBYX clinical trials

US Patents and Regulatory Information for CEREBYX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Parke Davis CEREBYX fosphenytoin sodium INJECTABLE;INJECTION 020450-001 Aug 5, 1996 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for CEREBYX

See the table below for patents covering CEREBYX around the world.

Country Patent Number Title Estimated Expiration
Denmark 0473687 ⤷  Sign Up
Czech Republic 277918 INJECTABLE, AQUEOUS PHARMACEUTICAL PREPARATION FOR TREATING AND CURE OF CONVULSIVE STATES ⤷  Sign Up
Germany 69026253 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for CEREBYX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0473687 SPC/GB98/030 United Kingdom ⤷  Sign Up PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
0473687 99C0008 Belgium ⤷  Sign Up PRODUCT NAME: FOSPHENYTOINUM DINATRICUM; REGISTRATION NO/DATE: 19 IS 102 F12 19980901; FIRST REGISTRATION: GB PL00019/1057 19980204
0473687 C980045 Netherlands ⤷  Sign Up PRODUCT NAME: FOSPHENYTOINUM-DI-NATRICUM; NATL REGISTRATION NO/DATE: RVG 22758 19980702; FIRST REGISTRATION: GB PL 00019/0157 19980204
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.